Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72


Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase.

Liu Y, Shreder KR, Gai W, Corral S, Ferris DK, Rosenblum JS.

Chem Biol. 2005 Jan;12(1):99-107.


Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects.

Liu Y, Jiang N, Wu J, Dai W, Rosenblum JS.

J Biol Chem. 2007 Jan 26;282(4):2505-11. Epub 2006 Nov 29.


The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.

Li L, Wang X, Chen J, Ding H, Zhang Y, Hu TC, Hu LH, Jiang HL, Shen X.

Acta Pharmacol Sin. 2009 Oct;30(10):1443-53. doi: 10.1038/aps.2009.141.


Polo-like kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitination in human cells.

Eckerdt F, Yuan J, Saxena K, Martin B, Kappel S, Lindenau C, Kramer A, Naumann S, Daum S, Fischer G, Dikic I, Kaufmann M, Strebhardt K.

J Biol Chem. 2005 Nov 4;280(44):36575-83. Epub 2005 Aug 23.


In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, Noro N, Furuta M, Emmitte KA, Gilmer TM, Mook RA Jr, Cheung M.

Mol Cancer Ther. 2007 Feb;6(2):450-9. Epub 2007 Jan 31.


Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands.

Elling RA, Fucini RV, Romanowski MJ.

Acta Crystallogr D Biol Crystallogr. 2008 Sep;64(Pt 9):909-18. doi: 10.1107/S0907444908019513. Epub 2008 Aug 13.


Polo-like kinase 1 inhibits the activity of positive transcription elongation factor of RNA Pol II b (P-TEFb).

Jiang L, Huang Y, Deng M, Liu T, Lai W, Ye X.

PLoS One. 2013 Aug 16;8(8):e72289. doi: 10.1371/journal.pone.0072289. eCollection 2013.


Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.

Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z.

Anticancer Drugs. 2011 Jun;22(5):444-53. doi: 10.1097/CAD.0b013e32834513f4.


Polo-like kinases in AML.

Berg T, Bug G, Ottmann OG, Strebhardt K.

Expert Opin Investig Drugs. 2012 Aug;21(8):1069-74. doi: 10.1517/13543784.2012.691163. Epub 2012 Jun 6.


Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.

Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Menendez JA.

Cell Cycle. 2011 Apr 15;10(8):1295-302. Epub 2011 Apr 15.


Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.

Lin YC, Sun SH, Wang FF.

Cell Signal. 2011 Nov;23(11):1816-23. doi: 10.1016/j.cellsig.2011.06.016. Epub 2011 Jun 29.


Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.

Lan R, Lin G, Yin F, Xu J, Zhang X, Wang J, Wang Y, Gong J, Ding YH, Yang Z, Lu F, Zhang H.

Lab Invest. 2012 Oct;92(10):1503-14. doi: 10.1038/labinvest.2012.114. Epub 2012 Aug 13.


Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin.

Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT.

Cancer Res. 1998 Oct 1;58(19):4375-82.


Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines.

Fink J, Sanders K, Rippl A, Finkernagel S, Beckers TL, Schmidt M.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3189-97.


Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.

Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.

Chem Biol. 2008 May;15(5):459-66. doi: 10.1016/j.chembiol.2008.03.013.


Biological impact of freezing Plk1 in its inactive conformation in cancer cells.

Keppner S, Proschak E, Kaufmann M, Strebhardt K, Schneider G, Spänkuch B.

Cell Cycle. 2010 Feb 15;9(4):761-73. Epub 2010 Feb 16.


Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.

Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Knipstein J, Dubuc A, Taylor MD, Handler MH, Foreman NK, Vibhakar R.

BMC Cancer. 2012 Mar 5;12:80. doi: 10.1186/1471-2407-12-80.


Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.

Thrum S, Lorenz J, Mössner J, Wiedmann M.

Anticancer Res. 2011 Oct;31(10):3289-99.


Supplemental Content

Support Center